- Home
- ABVC vs HOOK Comparison
ABVC vs HOOK Comparison
Compare ABVC & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- HOOK
- Stock Information
- Founded
- ABVC 2015
- HOOK 2011
- Country
- ABVC United States
- HOOK United States
- Employees
- ABVC N/A
- HOOK N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- HOOK Health Care
- Exchange
- ABVC Nasdaq
- HOOK Nasdaq
- Market Cap
- ABVC 16.7M
- HOOK 9.3M
- IPO Year
- ABVC N/A
- HOOK 2019
- Fundamental
- Price
- ABVC $0.98
- HOOK $0.85
- Analyst Decision
- ABVC
- HOOK Buy
- Analyst Count
- ABVC 0
- HOOK 4
- Target Price
- ABVC N/A
- HOOK $10.67
- AVG Volume (30 Days)
- ABVC 655.9K
- HOOK 38.6K
- Earning Date
- ABVC 04-15-2025
- HOOK 05-08-2025
- Dividend Yield
- ABVC N/A
- HOOK N/A
- EPS Growth
- ABVC N/A
- HOOK N/A
- EPS
- ABVC N/A
- HOOK N/A
- Revenue
- ABVC $509,588.00
- HOOK $43,946,000.00
- Revenue This Year
- ABVC $735.18
- HOOK N/A
- Revenue Next Year
- ABVC N/A
- HOOK N/A
- P/E Ratio
- ABVC N/A
- HOOK N/A
- Revenue Growth
- ABVC 234.31
- HOOK 118.32
- 52 Week Low
- ABVC $0.40
- HOOK $0.72
- 52 Week High
- ABVC $1.73
- HOOK $10.50
- Technical
- Relative Strength Index (RSI)
- ABVC 56.38
- HOOK 39.54
- Support Level
- ABVC $0.81
- HOOK $0.73
- Resistance Level
- ABVC $1.00
- HOOK $0.85
- Average True Range (ATR)
- ABVC 0.16
- HOOK 0.08
- MACD
- ABVC -0.01
- HOOK 0.03
- Stochastic Oscillator
- ABVC 39.92
- HOOK 77.25
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.